HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target

FDA Grants Rein Therapeutics Fast Track Designation For LTI-03

Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03

Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share

Rein Therapeutics Announces Nature Communications Publication Of First-In-Human LTI-03 Data In 24 IPF Patients, Says Drug Reduced Multiple Fibrosis And Inflammation Markers